Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OPGEN INC : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)

06/09/2021 | 05:05pm EDT

Item 5.07 - Submission of Matters to a Vote of Security Holders.

On June 9, 2021, OpGen, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). The Annual Meeting was adjourned to July 7, 2021, solely with respect to the voting on Proposal 2 relating to the approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of capital stock from 60,000,000 to 110,000,000 shares and authorized number of shares of common stock from 50,000,000 to 100,000,000 shares ("Proposal 2").

At the Annual Meeting, the total number of shares represented in person or by proxy was 16,493,679 of the 38,266,482 shares of common stock outstanding and entitled to vote at the Annual Meeting as of the record date, April 15, 2021. The following matters were voted upon at the Annual Meeting:

1.   Proposal 1 - Election of Directors. The election of the following named
persons to serve as directors of the Company until the 2022 Annual Meeting of
Stockholders or until their successors are elected and qualified. The votes cast
were as follows:

                                                   Vote           Broker
          Nominee                   For          Withheld        Non-Vote

William E. Rhodes, III           6,935,902       1,826,245       7,731,532
Mario Crovetto                   6,926,709       1,835,438       7,731,532
R. Donald Elsey                  6,930,788       1,831,359       7,731,532
Prabhavathi Fernandes, Ph.D.     6,964,100       1,798,047       7,731,532
Oliver Schacht, Ph.D.            6,968,569       1,793,578       7,731,532

2. Proposal 3 - Ratification of Appointment of Independent Accounting Firm. The ratification of the appointment of CohnReznick, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The votes cast were as follows:

                      15,355,710 votes FOR the proposal
                         599,529 votes AGAINST the proposal
                         538,438 votes ABSTAIN
                              2 votes  Broker Non-Votes

3.   Proposal 4 - Say on Pay. The advisory vote to approve the compensation paid
to the Company's named executive officers for 2020. The votes cast were as

                       6,675,525 votes FOR the proposal
                       1,674,971 votes AGAINST the proposal
                         411,651 votes ABSTAIN
                       7,731,532 votes Broker Non-Votes

4. Proposal 5 - Frequency of Say on Pay. The advisory vote regarding the frequency of submission of future say on pay votes to the stockholders. The votes cast were as follows:

                        2,374,327 votes Every ONE year
                        5,057,697 votes Every TWO years
                          438,759 votes Every THREE years
                          891,362 votes ABSTAIN
                        7,731,534 votes Broker Non-Votes

Based on the results of this vote, and consistent with the Board of Directors' recommendation, the Company intends to include an advisory stockholder vote to approve the compensation paid to its named executive officers every two years until the next required vote on the frequency of stockholder votes on the compensation of named executive officers. The Company is required to hold a vote on frequency every six years.

5. Proposal 6 - Adjournment. The approval of an adjournment of the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, Proposal 2. The votes cast were as follows:

                      13,234,926 votes FOR the proposal
                       2,842,595 votes AGAINST the proposal
                         416,155 votes ABSTAIN
                              3 votes  Broker Non-Votes

Adjournment with Respect to Proposal 2

The Annual Meeting was adjourned to July 7, 2021, solely with respect to Proposal 2 in order to provide additional time for stockholders to consider and vote on such proposal. The Annual Meeting will reconvene at 10:00 a.m. Eastern Time on July 7, 2021, at the offices of the Company located at 9717 Key West Ave, Suite 100, Rockville, MD 20850. As part of precautions regarding the coronavirus (or COVID-19) pandemic, the Company is planning for the possibility of the need to change the location of the Annual Meeting or to hold the Annual Meeting solely by means of remote communication. If such step is taken, the Company will announce the decision in advance and details on how to participate will be available on the Company's website at https://ir.opgen.com/.

Item 8.01 - Other Events.

On June 9, 2021, the Company issued a press release announcing the results of the Annual Meeting and the adjournment of the Annual Meeting solely with respect to Proposal 2. A copy of such press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed herewith:

99.1 Press release, dated June 9, 2021.

© Edgar Online, source Glimpses

All news about OPGEN, INC.
07:43aOPGEN : Corporate Presentation (PDF)
07:30aOPGEN : Achieves Key Development Milestone in Unyvero A30 RQ Platform Program
07/30SUPERNUS PHARMACEUTICALS : Pharma Says Named New CFO After Incumbent Resigned to..
07/29OPGEN INC : Change in Directors or Principal Officers (form 8-K)
07/29Opgen, Inc. Announces Resignation of Timothy C. Dec as Corporate Secretary, E..
07/07OPGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
07/07OpGen Announces Partial Adjournment of Annual Meeting
06/30OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AM..
06/28OpGen Group Company Ares Genetics Presents R&D Pipeline Updates
06/25OPGEN, INC.(NASDAQCM : OPGN) dropped from Russell Microcap Growth Index
More news
Financials (USD)
Sales 2021 7,79 M - -
Net income 2021 -35,6 M - -
Net Debt 2021 3,78 M - -
P/E ratio 2021 -2,66x
Yield 2021 -
Capitalization 100 M 100 M -
EV / Sales 2021 13,4x
EV / Sales 2022 5,43x
Nbr of Employees 102
Free-Float 99,8%
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Last Close Price 2,62 $
Average target price 5,50 $
Spread / Average Target 110%
EPS Revisions
Managers and Directors
Oliver Schacht Chief Executive Officer & Director
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.28.43%100
MODERNA, INC.231.78%139 174
LONZA GROUP AG25.60%58 688
CELLTRION, INC.-26.60%31 285
SEAGEN INC.-11.93%28 062